Therapeutic Efficacy of Gliptide (Sulglycotide 200 mg): A Double Blinded, Randomized, Active Drug Comparative, Multicenter Study.
10.7704/kjhugr.2013.13.3.173
- Author:
Jeong Seop MOON
1
;
Soo Heon PARK
;
Jong Jae PARK
;
Sang Woo LEE
;
Dong Ho LEE
;
Yong Chan LEE
;
Hwoon Yong JUNG
;
Jae Gyu KIM
;
Oh Young LEE
;
Jae J KIM
Author Information
1. Department of Internal Medicine, Seoul Paik Hospital, Inje University College of Medicine, Seoul, Korea.
- Publication Type:Multicenter Study ; Randomized Controlled Trial ; Original Article
- Keywords:
Sulglycotide;
Gastritis
- MeSH:
Alanine;
Edema;
Endoscopy;
Follow-Up Studies;
Gastritis;
Hemorrhage;
Humans;
Peptic Ulcer;
Quinolones;
Sialoglycoproteins
- From:The Korean Journal of Helicobacter and Upper Gastrointestinal Research
2013;13(3):173-181
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND/AIMS: Sulglycotide is a non-systemic drug, used in the treatment of peptic ulcer and gastritis. The aim of this study was to assess the therapeutic effect and safety of Gliptide (sulglycotide 200 mg) in comparison with Mucosta (rebamipide 100 mg) for treatment of gastritis. MATERIALS AND METHODS: Two hundred and three symptomatic patients with erosive gastritis at endoscopy were randomized to receive sulglycotide or rebamipide for four weeks. Therapeutic effects of the drugs for gastritis were evaluated by follow up endoscopic scoring systems and clinical symptoms. We also sought possible adverse effects of the two drugs. RESULTS: Gliptide (sulglycotide) and Mucosta (rebamipide) treatment in symptomatic gastritis resulted in endoscopic improvement rates of gastritis by 52.0%, 60.6% in intention-to-treat (ITT) analysis, 53.4%, 61.1% in per protocol (PP) analysis, which means therapeutic effects was not different between the two groups. The symptom improvement rates in the sulglycotide and rebamipide treated group were 57.3%, 57.5% in ITT analysis, 54.7%, 58.8% in PP analysis, which mean statistically no significant difference between the two groups. Endoscopic findings such as cure rates of erosion, edema, improvement rates of redness, hemorrhage were not significantly different between the two groups. No statistical significant differences were observed for adverse events between the two groups. The results of 95% CIs for the difference in endoscopic improvement rate and symptom improvement rate met the criteria for the non-inferiority of sulglycotide to rebamipide. CONCLUSIONS: These results demonstrate that Gliptide (sulglycotide) was not inferior to Mucosta (rebamipide) for endoscopic and symptomatic improvements for symptomatic erosive gastritis.
